Since the 1971 proposition that angiogenesis inhibition could serve as an effective cancer treatment strategy, numerous angiogenic regulators have been identified, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), angiopoietin, and basic fibroblast growth factor (bFGF). Here, FGF2 is linked to cancer.